PREPARATION OF CARBAMAZEPINE CHITOSAN NANOPARTICLES FOR IMPROVING NASAL ABSORPTION
In this study the nasal administration of carbamazepine has been studied using chitosan nanopartcles. The chitosan nanoparticles were prepared by ionic gelation of chitosan (100-300mg) with Tripolyphosphate sod (100-300mg in 100ml. Nine formulations were prepared, characterized and compared in terms of morphology (Transmission electron microscopy), drug content, particle size (zetasizer) and In-vitro drug release. In-vitro drug release studies were performed in Franz diffusion cell using phosphate buffer (buffer pH 5.5) as dissolution medium. The Chitosan nanoparticles had a mean size of 124.2Â±05 to 580Â±13nm, zeta potential were found to be +21 to 26.6 mV and the entrapment efficiency were found to be 65 to 72.7%. The in-vivo study was performed on Wistar rat, nanoparticles were administered through nasal route and compared with carbamazepine given by i.v. route, the results indicate that carbamazepine loaded chitosan nanoparticles enhances the drug absorption through nose. The results showed that the carbamazepine could be directly transported into the rat brain through nose and the possible side effects could be minimized.
Key Words: Carbamazepine, Chitosan Nanopartcles, Ionic Gelation, Epilepsy
2. Gavini E, Hegge A B, Rassu G, Sanna V, Testa C, Pirisino G, Karlsen J, Giunchedi, P, Nasal administration of carbamazepine using chitosan microspheres: In-vitro/in-vivo studies. Int. J. Pharm, 2006, 307, 9-15.
3. Barakat N S, Omar S A, Ahmed A A E, Carbamazepine uptake into rat brain following intra-olfactory transport, J. of Pharmacology, 2006, 58: 63â€“72
4. Lee, V H, Robinson J R, Controlled drug delivery fundamental and application second edition, revised and expanded. Dekker. New York. 2005, 29, 4.
5. Ravi MNV, Handbook of Particulate drug delivery, American Sci publishers, California, vol 2, 96-161.
6. Chein YW, Novel drug delivery systems, 2nd Ed. New York, Marcel Dekker Inc; 1993, 29, 269-300.
7. Yildiz O, Particulate carrier for nasal administration, handbook of particulate drug delivery, American scientific publisher, 2008 2,143-161.
8. Sharma, P K, Garg G, Salim M, "Review on nasal drug delivery system with recent advancemnt", Int. J. Pharm. and Pharma. sci., 2011, 3, 6-11.
9. Sharma S, Lohan S, Murthy RSR, Potential of Chitosan For Nose To Brain Drug Delivery Int. J. Pharm. Sci. Rev. Res., 2012,16(1), 09, 47-55.
10. Ugwoke M I, Kinget V N, J. Pharm.pharmacol, 2001, 53, 3.
11. Calvo P, Lopez C R, Vila-Jato J L, Alonso M J, J Appll Polym Sci, 1997, 63:125â€“132.
12. Lokhandwala H, Deshpande A, Deshpande S, Kinetic modeling and dissolution profiles comparison: an overview, Int. J. Pharm. Bio. Sci., 2013 4(1),728 â€“ 73
13. Dash S, Murthy P N, Nath L, Chowdhury P, Kinetic modeling on drug release from controlled, Drug delivery systems, Acta Polo. Pharm. Drug Rese, 2010, 67(3)217-223.
14. Chien, Nasal Drug Delivery and Delivery Systems, Drugs and the Pharma. Sci, 1991.
15. Sanghai B, Aggarwal G, HariKumar SL, Solid self microemulsifying drug deliviry system: a review, Journal of Drug Delivery and Therapeutics. 2013; 3(3):168-174
16. Jadhav K R, Manoj N, Gambhire, Shaikh I M, Nasal Drug Delivery System-Factors Affecting and Applications, Cur. Drug Therapy, 2007, 2, 27-38.
17. Banderas L M, "Nanostructures for Drug Delivery to the Brain", Cur. Med. Chem, 2011, 18(34), 5303-5321.
18. Mygind N, Dahl R, Anatomy and physiology of the nasal cavities in health and disease, adv. drug del. Rev, 1998, 29, 3-12.
19. Agnihotri S A, Mallikarjuna N N, Aminabhavi T M, Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J of Contr. Rel, 2004,100(1), 5-28,
20. Agnieszka Z, Wilczewska, Katarzyna N, Karolina H. Markiewicz, Halina C, Nanoparticles as drug delivery systems, Pharmacological Reports, 2012, 64, 1020-1037.
21. Vyas S P, Khar R K, Targeted And Controlled Drug Delivery: Novel Carrier System, Vallabh Prakashan, Delhi,2010 reprint
22. Kaur I P, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanopartic les in brain targeting, J. of Contr. Rel, 2008, 127, 97â€“109.
23. Yadav G, Panchory H, Nanosponges: A Boon to the Targeted Drug Delivery System, Journal of Drug Delivery & Therapeutics; 2013, 3(4), 151-155
24. MÃ¼ller, R H, MÃ¤der K, Gohla S, A review on SLNs for controlled drug delivery, Euro. J of Pharma. and Biopharma, 2000, 50(1),161-177.
25. Wong H, Rauth A M, Bendayan R, Wu X Y, In-vivo evaluation of a new polymer-lipid hybrid nanoparticles (PLN) formulation of doxorubicin in a murine solid tumor model, Euro. J of Pharma. and Biopharma, 2007, 65, 300â€“308.
26. Vyas, S P, Gowswami S K, Singh R, Liposamal based nasal delivery system of nifedipine: Delveloment and characterization, Int. J. Pharm, 1995, 118, 23-30.
27. Xiaoling G, Weixing T, Wei, L ,Qizhi Z, Xianguo X Y, Lectin- conjugated nanoparticles: preparation and brain delivery after intranasal administration, Biomaterial, 2006, 27, 3, 482-490.
28. Soppimath, K S, Aminabhavi T M, Kulkarni A R, Rudzinski W E, Biodegradable polymeric nanoparticles as drug delivery devices. J. Con. Rel, 2001, 70, 1-20.
29. Packhaeuser C B, Schnieders J, Oster C G, Kissel T, In situ forming parenteral drug delivery systems: an overview, Eur. J. Pharm. Biopharm, 2004, 58, 445-55.
30. Nagai T, Nambu NY, powder dosage of insulin for nasal administration, J. Con. Rel, 1984, 1, 15-22.
31. Heiati H, Tawashi R, Phillips N C, Solid lipid nanoparticles as drug carriers II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3%-azido-3% deoxythymidine palmitate in mice, Int. J. Pharm, 1998, 174, 71â€“80.
32. Gizurarson S, Thorvaldsson T P, Sigurdsson G E, Selective delivery of insulin into the brain: Intraolfactory absorption, Int. J. Pharm vol, 1997, 146,135-141
33. Ikechukwa M, Ugwoke, Nasal mucoadhesive delivery of antiparkinson drug, apomorphine: influence of drug-loading on in-vitro and in-vivo release in rabbits Int. J. Pharma, 1999, 181(1)125-138.
34. Garg A, Gupta MM, Mouth dissolving tablets: a review, Journal of Drug Delivery and Therapeutics. 2013; 3(2):207-214
35. Bagger M, Bechgaard E, A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. Int. J. Pharm, 2004, 269, 311-322.
36. Mascha P, Berg V D, Verhoef J C, Romeijn S G, Merkus F, Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur. J. Pharm. Biopharm, 2004, 58, 131â€“135.
37. Venkateswarlu V, Manjunath K, Preparation, characterization and in-vitro release kinetics of clozapine solid lipid nanoparticles, J. of Cont. Rel, 2004, 95, 627â€“638.
38. Carsten O, Lipid Drug Conjugate Nanoparticles of Hydrophilic Drug Diminazene- Cytotoxicity Testing and Mouse Serum Absorption, J. Con Rel.200418, 96(3)425-435.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).